Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center in Asia
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal to build integrated Bangalore facility cements ten-year partnership between the U.S. pharma and the Indian contract research organization.
You may also be interested in...
Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound
Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.